Bristol-Myers is sued for $6.4 billion over delayed cancer drug

Bristol Myers Squibb Co (BMY.N) was sued for $6.4 billion on Thursday for allegedly delaying its Breyanzi cancer drug to avoid payments to shareholders of the former Celgene Corp, which the drugmaker bought in 2019.